- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: HHS OIG Cites MA Plans; Shifts in Place of Death; FDA Warns Drugmaker
The HHS’ Office of the Inspector General (OIG) released a report that says Medicare Advantage (MA) plans received an estimated $6.7 billion in 2017 after adding diagnoses to patients' files that were not supported by their medical records; more Americans are dying at home rather than in hospitals or nursing homes; the FDA warned Alkermes, maker of Vivitrol, a long-acting antiaddiction medication, that its printed advertisement does not include the risk of an increased chance of a “potentially fatal” opioid overdose as the effects wear off.
Inspector General Says MA Plans Received Billions From Adding Unsupported Diagnoses
The HHS’ Office of the Inspector General released a report that says Medicare Advantage (MA) plans received an estimated $6.7 billion in 2017 after adding diagnoses to patients’ files that were not supported by their medical records. Reuters reported that MA plans added diagnoses for diabetes, heart disease, and other conditions in 99.3% of chart reviews of patient information and deleted incorrect diagnoses less than 1% of the time. The deleted information cut government payments by nearly $200 million, netting $6.7 billion.
More Americians Dying at Home, Not Hospitals, Nursing Homes
More Americans are dying at home rather than in hospitals or nursing homes, according to a report published in The New England Journal of Medicine. The report used government health statistics on deaths from natural causes from 2003 through 2017. Hospital deaths fell from 40% to 30% over that period and deaths in nursing homes from 24% to 21%. The shift to home deaths—not seen in about a hundred years or more—reflects more hospice care and progress toward the kind of end-of-life care that most people say they want.
FDA Warns Alkermes That Vivitrol Ad Lacks Information About Potential Risk of Overdose
The FDA warned Alkermes, maker of Vivitrol, a long-acting antiaddiction medication, that its printed advertisement does not include the risk of an increased chance of a “potentially fatal” opioid overdose as the effects wear off. Vivitrol, a long-acting version of naltrexone, is administered by injection every 28 days. If patients miss a dose or stop using it altogether, they risk overdosing if they take a legal or illegal opioid in the same amount they were previously consuming, The Washington Post reported.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
